comparative effectiveness

Interview

Improving Access to Quality Cancer Care Close to Home

12/13/2016

JCP Editors

Patients with cancer are often forced to choose between seeking specialized medical treatment at facilities located a significant distance from their homes or accepting less rigorous care at local treatment centers....

...

12/13/2016

Journal of Clinical Pathways

Research in Review

Hormone Receptor-Negative Breast Cancers Gain Greatest Economic Benefit from Trastuzumab

12/13/2016

JCP Editors

The cost-effectiveness of adjuvant trastuzumab (Herceptin, Genentech) may vary based on patient age and disease subtype among women with HER2-positive breast cancer, according to study results published in PLoS...

The...

12/13/2016

Journal of Clinical Pathways

Research in Review

Few RCTs of New Systemic Therapies Met ESMO Guidelines for Meaningful Outcomes

12/13/2016

JCP Editors

Fewer than one-third of randomized controlled trials reporting statistically significant outcomes for novel systemic therapies in solid cancers met the European Society of Medical Oncology’s (ESMO) threshold for...

Fewer...

12/13/2016

Journal of Clinical Pathways

Research in Review

Switching From Docetaxel to Paclitaxel and Bevacizumab Improves PFS in NSCLC

12/08/2016

JCP Editors

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new...

...

12/08/2016

Journal of Clinical Pathways

Few Blood Cancer Patients Receive Recommended CINV Prophylaxis

11/30/2016

JCP Editors

Many patients with hematologic cancers receiving highly emetic chemotherapy regimens do not achieve adequate control of chemotherapy-induced nausea and vomiting (CINV), according to study results presented at the...

Many...

11/30/2016

Journal of Clinical Pathways

Research in Review

11/30/2016

JCP Editors

Two kinds of heart medications, angiotensin-converting enzyme (ACE) inhibitors and beta blockers, can help to prevent a decline in heart function from breast cancer treatment, according to new research published in...

Two...

11/30/2016

Journal of Clinical Pathways

Research in Review

Incorporating EGFR, ALK Gene Alterations Data Improves Survival Prediction for Patients With NSCLC

11/21/2016

JCP Editors

Patients with non-small cell lung cancer (NSCLC) may see improved survival predictions as a result of a new prognostic tool that includes EGFR and ALK gene alterations data, according to an analysis published...

...

11/21/2016

Journal of Clinical Pathways

Research in Review

Improved Survival from Neoadjuvant Chemotherapy for Soft-Tissue Sarcoma

11/10/2016

JCP Editors

Neoadjuvant chemotherapy with epirubicin plus ifosfamide improves outcomes in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, according to a study presented at the...

...

11/10/2016

Journal of Clinical Pathways

Research in Review

Primary Prophylaxis for Breast Cancer Offers Little Benefit

11/07/2016

JCP Editors

The use of white blood cell growth stimulating factor drugs to reduce risk of neutropenia-related complications in women with breast cancer receiving common first-cycle chemotherapies had only a low-to-modest benefit...

The...

11/07/2016

Journal of Clinical Pathways

Research in Review

Pembrolizumab More Cost Effective Than Docetaxel for PD-L1-Positive NSCLC

10/31/2016

JCP Editors

The associated improvement in survival and quality-adjusted life years (QALYs) makes pembrolizumab a more cost-effective option than docetaxel for patients with programmed death ligand 1 (PD-L1)-positive non-small...

The...

10/31/2016

Journal of Clinical Pathways